Camurus (OM:CAMX) - Stock Price, News & Analysis

CAMX Stock Overview

A biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. More details

CAMX fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	6/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 71.5% below our estimate of its fair value

Earnings are forecast to grow 83.09% per year

Analysts in good agreement that stock price will rise by 36.4%

Risk Analysis

Shareholders have been diluted in the past year

Profit margins (15.8%) are lower than last year (28.5%)

Camurus AB (publ) Competitors

Swedencare

OM:SECARE

SEK 7.1b

AddLife

OM:ALIF B

SEK 15.8b

Biotage

OM:BIOT

SEK 12.0b

BioGaia

OM:BIOG B

SEK 10.5b

Price History & Performance

Summary of all time highs, changes and price drops for Camurus
Historical stock prices
Current Share Price	SEK 546.00
52 Week High	SEK 715.00
52 Week Low	SEK 417.40
Beta	0.96
11 Month Change	-16.19%
3 Month Change	-21.55%
1 Year Change	22.42%
33 Year Change	226.95%
5 Year Change	521.16%
Change since IPO	727.27%

Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality

Nov 15

Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Nov 10

Recent updates

Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality

Nov 15

Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Nov 10

What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You

Aug 09

Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

Jul 19

We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease

Jul 12

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

May 02

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Nov 11

We Think Camurus' (STO:CAMX) Profit Is Only A Baseline For What They Can Achieve

Feb 22

Shareholder Returns

	CAMX	SE Pharmaceuticals	SE Market
7D	-12.2%	-8.8%	-3.6%
1Y	22.4%	7.7%	12.3%

Return vs Industry: CAMX exceeded the Swedish Pharmaceuticals industry which returned 12.4% over the past year.

Return vs Market: CAMX exceeded the Swedish Market which returned 13.4% over the past year.

Price Volatility

Is CAMX's price volatile compared to industry and market?
CAMX volatility
CAMX Average Weekly Movement	5.7%
Pharmaceuticals Industry Average Movement	11.0%
Market Average Movement	5.6%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.3%

Stable Share Price: CAMX has not had significant price volatility in the past 3 months compared to the Swedish market.

Volatility Over Time: CAMX's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1991	225	Fredrik Tiberg	www.camurus.com

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon.

Camurus AB (publ) Fundamentals Summary

How do Camurus's earnings and revenue compare to its market cap?
CAMX fundamental statistics
Market cap	SEK 32.11b
Earnings (TTM)	SEK 266.21m
Revenue (TTM)	SEK 1.69b

120.6x

P/E Ratio

19.0x

P/S Ratio

Is CAMX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CAMX income statement (TTM)
Revenue	SEK 1.69b
Cost of Revenue	SEK 128.76m
Gross Profit	SEK 1.56b
Other Expenses	SEK 1.29b
Earnings	SEK 266.21m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 13, 2025

Earnings per share (EPS)	4.53
Gross Margin	92.38%
Net Profit Margin	15.76%
Debt/Equity Ratio	0%

How did CAMX perform over the long term?

See historical performance and comparison

CAMX Stock Overview

Rewards

Risk Analysis

Camurus AB (publ) Competitors

OM:SECARE

SEK 7.1b

OM:ALIF B

SEK 15.8b

OM:BIOT

SEK 12.0b

OM:BIOG B

SEK 10.5b

Price History & Performance

Recent News & Updates

Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality

Camurus AB (publ), Annual General Meeting, May 27, 2025

Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (publ) to Report Q1, 2025 Results on May 15, 2025

Camurus Provides Regulatory Update on the US NDA for CAM2029 in Acromegaly

Recent updates

Investors Can Find Comfort In Camurus' (STO:CAMX) Earnings Quality

Camurus AB (publ), Annual General Meeting, May 27, 2025

Camurus AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Camurus AB (publ) to Report Q1, 2025 Results on May 15, 2025

Camurus Provides Regulatory Update on the US NDA for CAM2029 in Acromegaly

President exercised options to buy kr81m worth of stock.

President recently sold kr39m worth of stock

What Camurus AB (publ)'s (STO:CAMX) P/S Is Not Telling You

New minor risk - Insider selling

Chief Technology Officer recently sold kr6.8m worth of stock

Earnings Miss: Camurus AB (publ) Missed EPS By 11% And Analysts Are Revising Their Forecasts

Second quarter 2024 earnings: EPS misses analyst expectations

Camurus Announces Positive Phase 3 Results from the Acroinnova 2 Study of Octreotide Sc Depot (Cam2029) in Acromegaly Patients

We Ran A Stock Scan For Earnings Growth And Camurus (STO:CAMX) Passed With Ease

Camurus Announces the Publication in JAMA Network Open of A New Post H Holes Analysis from A 24-Week Randomized, Double-Blind, Phase 3 Study

Camurus Receives EMA Acceptance of MAA Filing for Octreotide SC Depot (Cam2029) for the Treatment of Acromegaly

Chief Technology Officer recently sold kr845k worth of stock

Consensus EPS estimates increase by 18%

First quarter 2024 earnings released: EPS: kr1.36 (vs kr1.06 in 1Q 2023)

Camurus AB (publ)'s (STO:CAMX) CEO Will Probably Have Their Compensation Approved By Shareholders

Investors Appear Satisfied With Camurus AB (publ)'s (STO:CAMX) Prospects

Camurus AB (Publ) Announces Board Resignations

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB (Publ) Announces FDA Acceptance of NDA Submission for Oclaiz™ for Treatment of Acromegaly

Camurus' (STO:CAMX) Strong Earnings Are Of Good Quality

Consensus EPS estimates fall by 39%

With EPS Growth And More, Camurus (STO:CAMX) Makes An Interesting Case

Full year 2023 earnings: EPS misses analyst expectations

Camurus AB Provides Earnings Guidance for the Full Year 2024

Camurus AB Appoints Behshad Sheldon as President of Camurus Inc. and Member of the it's Executive Management Team, Starting 1 April 2024

Camurus AB (Publ) Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease

Investor sentiment deteriorates as stock falls 15%

Price target increased by 8.2% to kr550

Camurus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 1.09 billion.

Camurus AB (publ) Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly

Camurus AB (publ) (STO:CAMX) Investors Are Less Pessimistic Than Expected

President exercised options to buy kr86m worth of stock.

Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors

Price target increased by 16% to kr471

Investor sentiment improves as stock rises 20%

Need To Know: Analysts Are Much More Bullish On Camurus AB (publ) (STO:CAMX) Revenues

Camurus AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 9.1% to kr351

Camurus AB (Publ) Raises Earnings Guidance for the Year 2023

Camurus AB (publ), Annual General Meeting, May 08, 2024

Insider recently sold kr295k worth of stock

Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn

Camurus AB (Publ) Provides Earnings Outlook for the Year 2023

New major risk - Earnings quality

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot (Cam2029) in Patients with Acromegaly

Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly

President recently sold kr23m worth of stock

Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder

Consensus EPS estimates increase by 21%

Consensus EPS estimates increase by 25%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind